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Abstract
Background: Resting tremor is common in Parkinson’s disease (PD), but up to 47% of PD patients have action tremor, which is sometimes resistant to
medications. Deep brain stimulation (DBS) of the ventral intermediate nucleus (VIM) of the thalamus or subthalamic nucleus (STN) is effective for medication-
refractory tremor in PD, though it remains unclear whether STN DBS is as effective as VIM DBS for postural/action tremor related to PD.
Methods: We carried out a single-center retrospective review of patients with medication-refractory resting, postural, and action PD tremor, treated with either
VIM or STN DBS between August 2004 and March 2014. We assessed the degree of improvement using items 20 and 21 of the Unified Parkinson’s Disease Rating
Scale (UPDRS) motor scale and examined the proportion of patients achieving tremor arrest.
Results: A total of 18 patients were analyzed, 10 treated with STN and eight treated with VIM, with similar off-medication motor UPDRS scores. There was no
significant difference in improvement in tremor scores or in the proportion of patients experiencing tremor arrest between the two stimulation sites. Overall, 56%
and 72% of patients experienced complete absence of postural/action tremor and resting tremor, respectively, at last follow-up.
Discussion: This study demonstrated excellent outcomes on both resting and postural/action tremor after either VIM or STN DBS. Resting tremor improved to a
greater degree than postural/action tremor in both groups. These results suggest that a large randomized controlled trial is needed to show a superior effect of one
target on PD tremor.
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Introduction
Although resting tremor is one of the most characteristic features of
Parkinson’s disease (PD), as many as 47%1 of PD patients have action
tremor, which is likely to be intrusive in daily tasks. Some patients with
resting tremor exhibit only mild and non-progressive bradykinesia,
rigidity, or gait disturbance. This syndrome is recognized as tremor-
predominant parkinsonism or benign tremulous parkinsonism (BTP) and
includes resting tremor and, in many cases, moderate to marked postural
tremor.2 Similar to the resting tremor of typical PD, action tremor in PD
may also be resistant to medications, including levodopa.2,3
Deep brain stimulation (DBS) of the ventral intermediate nucleus
(VIM) of the thalamus is an effective treatment for medication-
refractory tremor in both essential tremor (ET) and PD4–6 but does not
improve other parkinsonian features. In contrast, subthalamic nucleus
(STN) DBS improves tremor, as well as bradykinesia, rigidity, and
levodopa-related motor complications.7,8 In patients with severe,
medication-refractory PD tremor, the degree of benefit for the resting,
postural, and action components of tremor are relevant when deciding
which structure should be targeted. Only a few studies have examined
the efficacy of these two targets for treatment of tremor while none of
these has compared the response of resting and postural/action tremor
to DBS at the two sites.3,9,10
We carried out a retrospective review of patients in our center with
BTP who had medication-refractory postural and action tremors that
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were treated with either VIM or STN DBS and assessed the degree of
improvement with respect to each of these action tremor types.
Methods
This is an institutional review board-approved retrospective review
of 21 patients with medication-refractory PD-related tremor who were
treated at the Beth Israel Deaconess Medical Center with either VIM
or STN DBS between August 2004 and March 2014. All patients met
Queen Square Brain Bank Criteria for idiopathic PD.11 Criteria for
study inclusion included 1) the presence of both resting and postural
tremor with an action component .1 on items 20 and 21 of the
Unified Parkinson’s Disease Rating Scale (UPDRS) motor scale; 2) at
least one other cardinal feature of PD such as bradykinesia or rigidity;
3) lack of improvement in tremor despite multiple medication trials,
including dopamine agonists and levodopa. Patients with pure resting
tremor without an action component were excluded from this analysis.
The presence of motor fluctuations and/or dyskinesias was not an
exclusion criterion.
Details of the surgical procedure were described in a previous
publication.12 Proper lead localization was confirmed post-operatively
using either computerized tomography or magnetic resonance
imaging. Stimulation therapy was initiated 2–4 weeks after implanta-
tion of the electrodes. During the first 3 post-operative months,
stimulation parameters were adjusted to achieve optimal control of
tremor without side effects. Follow-up was performed at routinely
scheduled visits, usually every 3–6 months, unless the patient reported
an urgent complication or other issue. Clinical efficacy, stimulation
parameters, and impedance analyses were recorded at each follow-up
visit.
The charts of 21 patients were reviewed. Of these, we identified 18
patients who fulfilled the inclusion criteria. Two patients were excluded
because their tremor had only a rest or postural component. One
patient who required VIM and STN DBS to improve severe tremor
was also excluded. Tremor severity was evaluated using items 20 (rest
tremor) and 21 (action or postural tremor) of the UPDRS motor scale
(UPDRS III) for the contralateral hand. Each item ranges from 0 to 4,
with a larger score signifying more severe symptoms. Tremor scores
were recorded at baseline, after initial DBS programming, and at the
most recent follow-up visit. The Wilcoxon rank sum test was employed
to determine the statistical significance of differences in the postural
and action tremor (item 21) scores before and after DBS and to
compare the tremor score improvements achieved with each of the two
targets. A p value of 0.05 was considered to be statistically significant.
Results
Of the 18 patients who were included in the study, the mean age at
tremor onset was 54.8 years (SD 11.9, range 37–74 years) (Table 1).
Ten patients underwent STN DBS and eight patients underwent VIM
DBS. Each of the leads was implanted in the hemisphere contralateral
to the most affected side except for two patients who had staged
bilateral STN lead implants. Only the limb tremor contralateral to the
first side implanted was included for analysis to eliminate any question
of ipsilateral benefit. The two groups were similar in terms of age at
tremor onset, disease duration, and motor impairment as assessed by
the UPDRS III. The mean time from tremor onset to DBS surgery
was 10.5 years for the VIM group (range 5–27 years) vs. 9.8 years for
the STN group (range 3–32 years). Two patients had prolonged
tremor duration of 27 and 32 years, and were thought possibly to have
had ET preceding the onset of PD. The mean UPDRS III score in the
off-medication state was 29.2 and was not significantly different
between the two groups (VIM 30.6 vs. STN 28.2, p 5 0.81). Only two
of the subjects had peak-dose dyskinesias and wearing off.
There was no significant difference in the degree of improvement in
postural/action tremor scores generated by VIM thalamic vs. STN
DBS. Postural or action tremor (UPDRS item 21) improved 72% in
the VIM DBS group vs. 68% in the STN group (p 5 0.97). Patients
who received VIM thalamic DBS started with a mean baseline
postural/action tremor score (item 21) of 3.3 (SD 1.0, range 2–4),
which improved to 0.8 (SD 0.9, range 0–2). Patients receiving STN
DBS started from a mean baseline postural/action tremor score of 1.9
(SD 1.0, range 1–4) improving to 0.4 (SD 0.5, range 0–1). Of the nine
patients with a baseline postural/action tremor score of 3 or greater,
three received STN stimulation while six received VIM stimulation.
Each of these three had post-surgical tremor scores of zero at last
follow-up (range 24–60 months). Following programming, 10 of the 18
patients had complete absence of tremor. This represents 50% (four of
eight) of the patients treated with VIM DBS and 60% (six of 10) of
patients receiving STN DBS. In three subjects, neither postural nor
action tremor improved after programming (two STN, one VIM), but
these patients did demonstrate improved resting tremor, which had
been of greater severity.
There was a 91% improvement in rest tremor (UPDRS III item 20)
in the VIM group and an 89% improvement in the STN group (p 5
0.91). The baseline preoperative rest tremor scores were 3.1 (SD 1.4)
and 2.9 (SD 0.8) respectively, improving to 0.4 (SD 0.7) and 0.3 (SD
0.5) respectively. Thirteen of the 18 patients had complete absence of
rest tremor, scoring zero on item 20. This represented 75% (six of
eight) of the VIM group 70% (seven of 10) of the STN group.
We assessed whether there was any worsening of tremor comparing
the first post-programming visit to the most recent follow-up visit. The
mean postural/action tremor score increased slightly in the VIM
group from the first post-programming score to the most recent follow-
up visit based on three individuals who had worsened by at least a
point. There was only one individual in the STN group who had
worsening of postural/action tremor score and the difference in the
change scores did not reach statistical significance (p 5 0.45). In
contrast, the mean resting tremor score remained unchanged from
post-programming to most recent follow-up in both the STN and VIM
groups. The mean time to last follow-up was 40 months (range 1–108
months with slightly longer follow up in the VIM group (mean 48
months) vs. the STN group (mean 35 months). In addition, there
were no statistically significant differences in stimulation parameters
assessed at last follow-up (Table 1). Finally, adverse events in the two
groups were examined. Adverse events included post-operative
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Table 1. Comparison of Clinical Characteristics, Tremor Severity, and Programming Parameters by Target
VIM (n58) STN (n510)
M:F 7:1 8:2
Age at onset (mean, SD), years 54.7 ¡ 11.9 53.6 ¡ 13.3
Disease duration (mean, SD), years 10.5 ¡ 7.5 9.8 ¡ 9.1
Total off medication motor UPDRS score
(mean, SD)
30.6 ¡ 12.3 28.2 ¡ 14.6
Baseline postural/action score
Severe, 4 5 1
Moderately severe, 3 0 2
Moderate, 2 3 3
Mild, 1 0 4
Pre-surgery item 21 score (mean, SD) 3.3 ¡ 1.0 1.9 ¡ 1.0
Post-programming item 21 score (mean,
SD)
0.8 ¡ 0.9 0.4 ¡ 0.5
Rationale for target selection
Chief complaint action tremor 8





Younger age (age ,60) 2
Motor complications 2
Percentage improvement (mean, SD) 71.9 ¡ 36.4 68.1 ¡ 44.1
Complete postural/action tremor
suppression, number of patients (%)
4 (50%) 6 (60%)
Long-term post-surgery item 21 score
(mean, SD)
1.0 ¡ 0.8 0.3 ¡ 0.5
Pre-surgery item 20 score (mean, SD) 3.1 ¡ 1.4 2.9 ¡ 0.8
Post-programming item 20 score (mean,
SD)
0.4 +/_0.7 0.3 ¡ 0.5
Percentage improvement (mean, SD) 90.6 ¡ 18.6 88.9 ¡ 20.5
Complete rest tremor suppression, number
of patients (%)
6 (75%) 7 (70%)
Long-term post-surgery item 20 score
(mean, SD)
0.4 ¡ 0.7 0.2 ¡ 0.4
Length of follow-up (months, mean, SD) 48.0 ¡ 41.0 34.9 ¡ 24.0
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encephalopathy (one STN), worsening of gait (one STN), and
functional lower extremity weakness with DVT (one VIM).
Discussion
We compared the long-term improvement of resting with postural/
action tremor after VIM and STN DBS surgery. We found a
consistent improvement in both resting and postural/action tremor
with either VIM thalamic or STN stimulation, with 10 of the 18 (56%)
patients experiencing complete absence of postural/action tremor and
72% experiencing complete absence of resting tremor at last follow-up.
There was no significant difference between the two stimulation sites
regarding both mean tremor improvement and the proportion of
patients experiencing complete tremor control.
A prior study by Savica et al.3 demonstrated either complete
resolution or reduction in resting tremor in 87% of subjects receiving
either STN or thalamic stimulation. Action tremor was not assessed.
Two previous studies examined the impact of STN DBS on action
tremor, demonstrating improvements 1–2 years after surgery.9,10
Longer-term benefit was not examined. Studies examining the long-
term effects of DBS have mainly shown a benefit in resting tremor.5,6
In this analysis, we were able to demonstrate improvement in action
tremor with stimulation at either the VIM or STN, both after surgery
and at last follow-up, which occurred at a mean of 40 months. These
findings raise the possibility that either target may be reasonably
equivalent in treating parkinsonian postural/action tremor. In this
scenario the clinical decision-making regarding target selection may
need to focus on consideration of adverse effects, the possibility of
benefit on other features such as bradykinesia, rigidity, or dystonia, or
duration of benefit. In this study we were not able to detect any
difference in complication rates although we did not examine impact
on cognition, which may be the most fruitful area for study given
concerns about cognitive impairment after STN DBS.12
With respect to duration of benefit, we did observe increasing mean
tremor scores over time in three individuals in the VIM thalamic DBS
group; this was present in one subject in the STN DBS group.
Worsening tremor in the VIM thalamic DBS group is of interest in view
of the progressive decline in benefit demonstrated in patients with ET.13
It should be noted, however, that tremor was worse at baseline within
the VIM group and the length of follow-up in the VIM thalamic DBS
group was longer (48 months) than the STN DBS group (35 months).
Both of these factors may have biased the VIM DBS group towards
higher tremor scores at last follow-up. The difference in long-term
follow-up duration also likely reflects changes in clinical practice with
greater use of the VIM target earlier and a transition to the STN target
after its approval in 2002. In addition, our data suggest that target
preference tended towards VIM implantation in patients with more
severe baseline tremor even after Food and Drug Administration
approval of the STN target for PD. In this study, VIM stimulation
parameters were slightly higher than STN stimulation parameters,
which may reflect the fact that unilateral VIM stimulation may allow
for higher stimulation parameters to be used in severe tremor without
incurring unacceptable side effects. An alternative explanation is that
greater stimulation is required to achieve a satisfactory effect in VIM
DBS for severe parkinsonian postural/action tremor.
The specific neuroanatomic networks subserving action tremor and
resting tremor has been the subject of much debate and speculation. The
cerebellothalamocortical network is likely to be implicated in most types
of tremor, including resting tremor and action tremor,14 which would
suggest that VIM DBS would be beneficial for both types of tremor. In
particular, the postural tremor in PD may actually be a form of re-
emergent rest tremor, reappearing only when no other motor demands
are placed on the limb.15 However, whether parkinsonian action tremor
differs from other types of action tremor, as in ET, remains unclear.
Additionally, evidence that both VIM and STN networks overlap at the
motor cortex and that DBS at either site may interrupt tremor signals
transmitted through the motor cortex16 suggests that both may be
equally efficacious because of effects on the final common pathway.
This study has several limitations that may impact our conclusions.
Firstly, this was a retrospective study with limited power to detect a
meaningful difference in the percentage of patients experiencing
tremor suppression following either STN or VIM DBS for both resting
and postural/action components for parkinsonian tremor. We
conclude that DBS at both targets was effective in reducing, or
resolving the action component of parkinsonian tremor, in the short
Table 1. Continued
VIM (n58) STN (n510)
Monopolar vs. bipolar stimulation, Number
of leads (n520)
6:2 9:3
Voltage (mean, SD) 3.3 V ¡ 0.9 3.1 V ¡ 0.7
Pulse width (mean, SD) 98 ms ¡ 41.7 75 ms ¡ 23.9
Frequency (mean, SE) 164 Hz ¡ 27.2 163 Hz ¡ 28.9
F, Female; M, Male; SD, Standard Deviation; SE, Standard Error; STN, Subthalamic Nucleus; UPDRS, Unified Parkinson’s Disease Rating Scale; VIM, Ventral Intermediate
Nucleus.
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and long term. Secondly, a formalized tremor rating scale was not
used to assess action tremor, but, instead, items 20 and 21 of the
UPDRS III were used to measure both postural and action tremor
severity.
In conclusion, we found excellent outcomes on both resting and
postural/action tremor after both VIM thalamic and STN DBS in
patients with medication-refractory action tremor. A high proportion
in both groups achieved post-programming and long-term follow-up
resting and postural/action tremor scores of zero with stimulation.
Based on the data showing similar efficacy in this study, prospective
studies with a very large sample size and randomized target selection
would be necessary to determine the comparative efficacy and
durability of VIM thalamic versus STN DBS stimulation in improving
tremor in patients with combined resting and action tremor associated
with PD.
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